| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Sadamori H, Yagi T, Shinoura S, Umeda Y, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Fujiwara T. | New surgical approach to large splenorenal shunt in living donor liver transplantation: diversion of SMV and SPV blood flow. | J Gastrointest | 17 | 403-7 | 2013 |
| Marubashi S, Wada H, Kawamoto K, Kobayashi S, Eguchi H, Doki Y, Mori M, Nagano H, | Laparoscopy-assisted hybrid left-side donor hepatectomy. | World J Surg | 37(9) | 2202-2210 | 2013 |
| Kobayashi S, Wada H, Hama N, Akita H, Kawamoto K, Eguchi H, Umeshita K, Doki Y, Mori M, Nagano H, | Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period. | Cancer Chemother Pharmacol | 72(6) | 1325-1333 | 2013 |
| Marubashi S, Kobayashi S, Wada H, Kawamoto K, Eguchi H, Doki Y, Mori M, Nagano H. | Hepatic artery reconstruction in living donor liver transplantation: risk factor analysis of complication and a role of MDCT scan for detecting anastomotic stricture. | World J Surg | 37(11) | 2671-2677 | 2013 |
| Egawa H, Teramukai S, Haga H, Tanabe M, Mori A, Ikegami T, Kawagishi N, Ohdan H, Kasahara M, Umeshita K. | Impact of Rituximab Desensitization on Blood-Type-Incompatible Adult Living Donor Liver Transplantation: A Japanese Multicenter Study. | Am J Transplant. | 14(1) | 102-114. | 2014 |

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Tatsukawa Y, Takahashi S, Kawaoka T, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. | Two patients treated with PEGIFN/RBV/TVR triple therapy for recurrent hepatitis C after living donor liver transplantation. | Hepatol Res. | | Epub ahead of print | 2014 |
| Onoe T, Tanaka Y, Ide K, Ishiyama K, Oshita A, Kobayashi T, Amano H, Tashiro H, Ohdan H. | Attenuation of Portal Hypertension by Continuous Portal Infusion of PGE1 and Immunologic Impact in Adult-to-Adult Living-Donor Liver Transplantation. | Transplantation. | 95(12) | 1521-1527 | 2013 |
| Ohdan H. | Is living donor liver transplantation really equivalent to deceased donor liver transplantation? | Transpl Int. | 26(8) | 778-779 | 2013 |
| Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Ohdan H, Tzakis AG. | Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-gamma production. | Transplant Proc. | 45(5) | 2045-2050 | 2013 |
| Matsushima H, Soyama A, Takatsuki M, Hidaka M, Muraoka I, Kuroki T, Eguchi S | The Outcomes of Patients with Severe Hyperbilirubinemia Following Living Donor Liver Transplantation | Dig Dis Sci | 58(5) | 1410-4 | 2013 |

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Matsuzaki T, Tatsuki I, Otani M, Akiyama M, Ozawa E, Miuma S, Miyaaki H, Taura N, Hayashi T, Okudaira S, Takatsuki M, Isomoto H, Takeshima F, Eguchi S, Nakao K. | Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. | J Gastroenterol Hepatol | 28(7) | 1217-22 | 2013 |
| Eguchi S, Takatsuki M, Soyama A, Torashima Y, Tsuji A, Kuroki T | False positivity for the human immunodeficiency virus antibody after influenza Vaccination in a living donor for liver transplantation | Liver Transpl | 19(6) | 666 | 2013 |
| Takatsuki M, Soyama A, Eguchi S | Liver transplantation for HIV/hepatitis C virus co-infected patients | Hepatol Res | 44(1) | 17-21 | 2014 |
| Eguchi S | Is low central venous pressure effective for postoperative care after liver transplantation? | Surg Today | 43(7) | 828-9 | 2013 |
| Egawa H, Nakanuma Y, Maehara Y, Uemoto S, Eguchi S, Sato Y, Shirabe K, Takatsuki M, Mori A, Yamamoto M, Tsubouchi H. | Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: A multicenter study in Japan. | Hepatol Res. | 43(5) | 502-7 | 2013 |
| Tanaka T, Takatsuki M, Soyama A, Torashima Y, Kinoshita A, Yamaguchi I, Adachi T, Kitasato A, Kuroki T, Eguchi S. | Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation | Ann transplant | 18 | 293-8 v2013 | 2013 |

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Eguchi S, Takatsuki M, Kuroki T | Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus co-infection: update in 2013. | J Hepatobiliary Pancreat Sci | | | 2013 |
| Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, Takahashi M, Takagi M, Tokunaga Y, Fukushima R, Munakata Y, Nishikawa K, Takagane A, Tanaka T, Sekishita Y, Kang Y, Sakamoto J, Tsuburaya A. | Combination Chemotherapy with S-1 plus Cisplatin for Gastric Cancer that Recurs after Adjuvant Chemotherapy with S-1: Multi-institutional Retrospective Analysis. | Gastric Cancer | 15 | 245-251 | 2012 |
| Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshimura K, Takabe K, Endo I. | High expressions of ATP-binding cassette transporter ABCC11 in the breast tumor are associated with aggressive subtypes and worse disease-free survival. | Breast Cancer Research and Treatment 137:773-782, 2013. | 137 | 773-782 | 2013. |
| Hironaka S, Ueda S, Yasui H, Nishina H, Tsuda M, Tsumura T, Sugimoto T, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. | A Randomized, Open-label, Phase III Study Comparing Irinotecan with Paclitaxel in Advanced Gastric Cancer Patients without Severe Peritoneal Metastasis after Failure of Prior Combination Chemotherapy using Fluoropyrimidine plus Platinum : WJOG4007 Trial. | J Clin Oncol (in press) | | | |

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Taketomi A, Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K, Maehara Y. | A rare point mutation in the Ras oncogene in hepatocellular carcinoma. | Surg Today | 43(3) | 289-92. | 2013 |
| Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y, Fujiyoshi M, Taketomi A, Nishimura S, Todo S. | Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. | Hepatology | 57(6) | 2314-25 | 2013 |
| Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H, Taketomi A. | Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma. | World J Surg Oncol | 10<br>11 | 1186/1477-7819<br>52 | 2013 |
| Tsuruga Y, Kamachi H, Wakayama K, Kakisaka T, Yokoo H, Kamiyama T, Taketomi A. | Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer. | World J Gastroenterol | 19(16) | 2569-73 | 2013 |
| Honda S, Miyagi H, Suzuki H, Minato M, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, Okada T, Taketomi A. | RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients. | Pediatr Surg Int | 29(11) | 1147-52 | 2013 |

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|---|---|---|---|---|
| Shibasaki S, Takahashi N, Toi H, Tsuda I, Nakamura T, Hase T, Minagawa N, Homma S, Kawamura H, Taketomi A. | Percutaneous transhepatic gallbladder drainage followed by elective laparoscopic cholecystectomy in patients with moderate acute cholecystitis under antithrombotic therapy. | J Hepatobiliary Pancreat Sci | 10 | 1002/jhbp.28 | 2013 |
| Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, Taketomi A. | Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. | World J Surg Oncol | 11(1) | 259 | 2013 |
| Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi M, Natsuizaka M, Suda G, Sho T, Hatanaka K, Matsuno Y, Yokoo H, Kamiyama T, Taketomi A, Fujii G, Tashiro K, Hikiba Y, Fujimoto M, Asaka M, Maeda S. | Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor κB/mitogen-activated protein kinase. | Carcinogenesis | | PMID:24130164 | 2013 |

ORIGINAL ARTICLE

# Sarcopenia Is a Prognostic Factor in Living Donor Liver Transplantation

**Toshiro Masuda,[1,2] Ken Shirabe,[1] Toru Ikegami,[1] Norifumi Harimoto,[1] Tomoharu Yoshizumi,[1] Yuji Soejima,[1] Hideaki Uchiyama,[1] Tetsuo Ikeda,[1] Hideo Baba,[2] and Yoshihiko Maehara[1]**

*[1]Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and [2]Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan*

The aims of this study were to investigate sarcopenia as a novel predictor of mortality and sepsis after living donor liver transplantation (LDLT) and to evaluate the effects of early enteral nutrition on patients with sarcopenia. Two hundred four patients undergoing preoperative computed tomography within the month before LDLT were retrospectively evaluated. The lengths of the major and minor axes of the psoas muscle were simply measured at the caudal end of the third lumbar vertebra, and the area of the psoas muscle was calculated. A psoas muscle area lower than the 5th percentile for healthy donors of each sex was defined as sarcopenia. Ninety-six of the 204 patients (47.1%), including 58.3% (60/103) of the male patients and 35.6% (36/101) of the female patients, were diagnosed with sarcopenia. Sarcopenia was independently and significantly associated with overall survival: there was an approximately 2-fold higher risk of death for patients with sarcopenia versus patients without sarcopenia (hazard ratio = 2.06, $P = 0.047$). Sarcopenia was an independent predictor of postoperative sepsis (hazard ratio = 5.31, $P = 0.009$). Other independent predictors were a younger recipient age ($P < 0.001$) and a higher body mass index ($P = 0.02$). Early enteral nutrition within the first 48 hours after LDLT was performed for 24.2% in 2003-2007 and for 100% in 2008-2011, and the incidence of postoperative sepsis for patients with sarcopenia (n = 96) was 28.2% (11/39) in 2003-2007 and 10.5% (6/57) in 2008-2011 ($P = 0.03$). In conclusion, sarcopenia is an independent predictor of mortality and sepsis after LDLT. The incidence of postoperative sepsis was reduced even in patients with sarcopenia after the routine application of early enteral nutrition. ***Liver Transpl 20:401-407, 2014***. © **2013 AASLD.**

Received August 25, 2013; accepted December 7, 2013.

*Sarcopenia* is a term used to describe skeletal muscle loss with aging.[1,2] Sarcopenia can occur in patients with a variety of chronic illnesses, such as cancer, cardiovascular disease, bone fractures, chronic liver disease, and malnutrition.[3] More than 40% of patients with liver cirrhosis reportedly have concomitant sarcopenia.[4]

An evaluation of muscle loss in patients with liver cirrhosis was recently reported to be an important and novel predictor of survival, although its mechanisms are not fully understood. Montano-Loza et al.[4] showed that sarcopenia was associated with mortality in patients with cirrhosis, but it did not correlate with the degree of liver dysfunction as evaluated with a conventional scoring system. A few reports regarding mortality after liver transplantation and sarcopenia have been recently published. Englesbe et al.[5] reported that central sarcopenia strongly correlated with mortality after deceased donor liver transplantation (DDLT). Kaido et al.[6] reported that patients with sarcopenia had worse survival after living donor liver transplantation (LDLT). Our first hypothesis is that sarcopenia is associated with outcomes and the rate of sepsis after LDLT.

**Abbreviations:** *a*, radius of the major axis; *b*, radius of the minor axis; BCAA, branched-chain amino acid; BMI, body mass index; DDLT, deceased donor liver transplantation; GV/SLV, graft volume/standard liver volume; LDLT, living donor liver transplantation; MELD, Model for End-Stage Liver Disease.

There were no grants or other financial support.

Address reprint requests to Ken Shirabe, M.D., Ph.D., F.A.C.S., Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. Telephone: +81-92-642-5466; FAX: +81-92-642-5482; E-mail: kshirabe@surg2.med.kyushu-u.ac.jp

DOI 10.1002/lt.23811
View this article online at wileyonlinelibrary.com.
LIVER TRANSPLANTATION.DOI 10.1002/lt. *Published on behalf of the American Association for the Study of Liver Diseases*

For the evaluation of central muscle loss, preoperative computed tomography scans were used to measure the psoas muscle area, which is a valid part of a sarcopenia evaluation. In many reports, this has been complicated by the fact that specific area-tracing software or manual tracing was needed to calculate the psoas muscle area. In the current study, to simplify the measurements, the lengths of the major and minor axes of the psoas muscle were measured. The area of the psoas muscle was simply approximated with the radii of the major and minor axes.

It has been reported that enteral nutrition prevents intestinal mucosal atrophy and preserves intestinal structure and functions.[7] Previously, we have reported the beneficial impact of early enteral nutrition within the first 48 hours after LDLT in reducing postoperative sepsis.[8] However, the actual impact of early enteral nutrition on patients with sarcopenia is not known. Our second hypothesis is that there are some differences in the impact of early enteral nutrition on patients with sarcopenia and patients without sarcopenia.

The aims of this study were (1) to investigate sarcopenia as a novel predictor of mortality and sepsis after LDLT and (2) to evaluate the effects of early enteral nutrition on patients with sarcopenia.

## PATIENTS AND METHODS

### Patients

Two hundred twenty-eight recipients of LDLT performed at Kyushu University Hospital between November 2003 and December 2011 were retrospectively investigated. Twenty-three patients with acute hepatic failure and 1 patient who died from operative blood loss were excluded from this study. Psoas muscle measurements from computed tomography were available for 204 recipients. Written informed consent was obtained from all patients. The institutional review board approved this study.

### Assessment of the Area of the Psoas Muscle

All study patients underwent preoperative computed tomography within the month before LDLT. Instead of using any area-measuring software, we simply measured the lengths of the major and minor axes of the psoas muscle at the caudal end of the third lumbar vertebra. The area of the psoas muscle was calculated with the following formula:

$$\text{Area} = a \times b \times \pi \quad (1)$$

where $a$ and $b$ are the radii of the major and minor axes, respectively.

In this study, for the definition of sarcopenia, we consulted our previous study of the cross-sectional area of the psoas muscle at the caudal end of the third lumbar vertebra of healthy donors.[9] An area of the psoas muscle lower than the 5th percentile for each sex was defined as sarcopenia. The cutoff levels were defined as 800 $cm^2$ for men and 380 $cm^2$ for women.[9]

### Evaluation of the Prognostic Factors After LDLT

Predictors of sarcopenia were evaluated only with preoperative values. The following were used as preoperative factors: recipient age, donor age, recipient sex, recipient status, preoperative renal failure, body mass index (BMI), Child-Pugh class, Model for End-Stage Liver Disease (MELD) score, and graft volume/standard liver volume (GV/SLV) ratio. Prognostic factors were investigated with the foregoing preoperative values and sarcopenia.

### Evaluation of the Correlation Between Sarcopenia and Postoperative Sepsis

Postoperative sepsis was defined as the isolation of bacteria other than common skin contaminants from a single blood culture within the first 3 months after transplantation along with clinical symptoms.[8,10] Risk factors for postoperative sepsis were investigated with the preoperative factors.

We introduced early enteral nutrition after LDLT in 2003. Initially, the adoption of enteral nutrition was determined on a case-by-case basis. Since 2008, early enteral nutrition via a nasojejunal tube has been routinely applied for all recipients within the first 24 hours after LDLT.[8] In order to evaluate the effects of early enteral nutrition on postoperative sepsis in patients with sarcopenia, the postoperative sepsis rates for patients with sarcopenia and patients without sarcopenia before and since 2008 were investigated.

### Statistical Analysis

All values are expressed as means and standard deviations. Univariate analyses were performed with the chi-square test or Fisher's exact probability test for categorical values and with the Mann-Whitney U test for continuous variables. Overall survival rates were calculated and compared with the Kaplan-Meier method and the log-rank test or Cox regression. Multivariate analyses were performed with the Cox proportional hazards regression model for overall survival. Differences with a $P$ value $< 0.05$ were considered to be significant. All statistical analyses were performed with StatView 5.0 (SAS Institute, Cary, NC).

## RESULTS

### Definition of Sarcopenia

The median calculated area of the psoas muscle was 530.6 $cm^2$ for all patients (range = 122.5-1667.5 $cm^2$), 760.9 $cm^2$ for male patients (range = 192.7-1667.5 $cm^2$), and 423.1 $cm^2$ for female patients (range = 122.5-1195.6 $cm^2$). Histograms of the area of the psoas muscle for all patients (Fig. 1A), male patients (Fig. 1B), and female patients (Fig. 1C) are shown. The histograms of all populations were normally distributed.




Figure 1. Histograms of the area of the psoas muscle for (A) all patients, (B) male patients, and (C) female patients. The histograms of all populations were normally distributed.

When we defined the cutoff levels as 800 $cm^2$ for men and 380 $cm^2$ for women on the basis of our previous data for healthy donors, 96 of the 204 patients (47.1%), including 58.3% (60/103) of the male patients and 35.6% (36/101) of the female patients, were diagnosed with sarcopenia.

Comparisons of the clinical characteristics of patients with sarcopenia and patients without sarcopenia are shown in Table 1. In the univariate analysis, the rates were higher in the sarcopenia group for the following variables: male sex ($P$ = 0.001), hospitalized ($P$ = 0.005), renal failure ($P$ = 0.04), Child-Pugh class C ($P$ = 0.02), and a MELD score $\geq$ 20 ($P$ = 0.01). Patients with sarcopenia had lower BMIs ($P$ = 0.004) than patients without sarcopenia. A logistic regression analysis revealed that a higher recipient age ($P$ = 0.05), male sex ($P$ < 0.001), and a lower recipient BMI ($P$ = 0.002) were associated with sarcopenia.

As for the diagnoses of the recipients, 12 of 26 patients (46.2%) with hepatitis B virus–positive cirrhosis, 45 of 103 patients (43.7%) with hepatitis C virus–positive cirrhosis, 12 of 27 patients (44.4%) with primary biliary cirrhosis, 7 of 10 patients (70.0%) with alcoholic cirrhosis, and 20 of 38 patients (52.6%) with other diagnoses suffered from sarcopenia ($P$ = 0.79).

## Prognostic Factors After LDLT

Patients with sarcopenia showed significantly worse overall survival in comparison with patients without sarcopenia ($P$ = 0.02; Fig. 2). The 3- and 5-year overall survival rates were 74.5% and 69.7%, respectively, for patients with sarcopenia and 88.9% and 85.4%, respectively, for patients without sarcopenia ($P$ = 0.02). Twenty-three patients with sarcopenia died during the follow-up period. The causes of death were postoperative sepsis for 26.1% (6/23), recurrence of hepatocellular carcinoma for 21.7% (5/23), postoperative bleeding for 13.0% (3/23), and other causes for 39.1% (9/23).

The univariate analysis showed that patients with a lower overall survival rate after LDLT correlated with higher rates of preoperative renal failure ($P$ = 0.01) and sarcopenia ($P$ = 0.02; Table 2). In the multivariate analysis, only sarcopenia (hazard ratio = 2.06, $P$ = 0.047) was an independent prognostic factor. Age, BMI, Child-Pugh score, MELD score, and GV/SLV ratio did not influence overall survival after LDLT.

## Sarcopenia and Postoperative Sepsis

Twenty-five of the 204 patients experienced postoperative sepsis. The rate of postoperative sepsis was 17.7% (17/96) for patients with sarcopenia and 7.4% (8/108) for patients without sarcopenia ($P$ = 0.03). Risk factors for postoperative sepsis were investigated. In the univariate analysis, recipient age ($P$ < 0.001), donor age ($P$ = 0.046), recipient status ($P$ = 0.03), preoperative renal failure ($P$ = 0.01), a MELD score $\geq$ 20 ($P$ = 0.04), and sarcopenia ($P$ = 0.03) were significant. A logistic regression analysis revealed that a lower recipient age ($P$ < 0.001), a higher BMI ($P$ = 0.02), and sarcopenia ($P$ = 0.009) were significant risk factors (Table 3).

The effects of early enteral nutrition on postoperative sepsis were investigated in patients with sarcopenia and patients without sarcopenia. Early enteral nutrition within the first 48 hours after LDLT was performed for 24.2% (24/99) in 2003-2007 and for 100% (105/105) in 2008-2011. The incidence of postoperative sepsis was 18.2% (18/99) in 2003-2007 and 6.7% (7/105) in 2008-2011 ($P$ = 0.02). In the

**TABLE 1. Comparison of the Clinical Characteristics of Patients With Sarcopenia and Patients Without Sarcopenia**

| Variable | No Sarcopenia (n = 108) | Sarcopenia (n = 96) | Univariate Analysis: *P* Value | Multivariate Analysis: Hazard Ratio | Multivariate Analysis: 95% Confidence Interval | Multivariate Analysis: *P* Value |
|---|---|---|---|---|---|---|
| Recipient age (years)* | 53.9 ± 10.5 | 54.8 ± 8.5 | 0.48 | 1.03 | 1.00-1.07 | 0.05 |
| Donor age (years)* | 34.4 ± 9.8 | 35.2 ± 11.2 | 0.59 | 1.01 | 0.98-1.04 | 0.50 |
| Recipient sex: male/female [% (n)] | 39.8 (43)/60.2 (65) | 62.5 (60)/37.5 (36) | 0.001 | 3.34 | 1.75-6.41 | <0.001 |
| Recipient status: hospitalized/home [% (n)] | 20.4 (22)/79.6 (86) | 38.5 (37)/61.5 (59) | 0.005 | 1.95 | 0.90-4.23 | 0.09 |
| Preoperative renal failure: yes/no [% (n)] | 2.8 (3)/97.2 (105) | 10.4 (10)/89.6 (86) | 0.04 | 2.02 | 0.44-9.23 | 0.37 |
| Recipient BMI (kg/m$^2$)* | 24.2 ± 3.6 | 22.8 ± 3.1 | 0.004 | 0.86 | 0.78-0.95 | 0.002 |
| Child-Pugh class: A + B/C [% (n)] | 38.9 (42)/61.1 (66) | 24.0 (23)/76.0 (73) | 0.02 | 1.42 | 0.68-2.97 | 0.35 |
| MELD score: ≥20/<20 [% (n)] | 10.2 (11)/89.8 (97) | 24.0 (23)/76.0 (73) | 0.01 | 2.46 | 0.95-6.37 | 0.06 |
| GV/SLV ratio (%)* | 40.7 ± 7.7 | 41.3 ± 8.5 | 0.62 | 0.99 | 0.96-1.03 | 0.72 |

*The data are presented as means and standard deviations.




Figure 2. Overall survival and sarcopenia. Patients with sarcopenia had significantly worse overall survival than patients without sarcopenia ($P$ = 0.02).

subgroup of patients without sarcopenia, the incidence of postoperative sepsis was 11.7% (7/60) in 2003-2007 and 2.1% (1/48) in 2008-2011 ($P$ = 0.07). In the subgroup of patients with sarcopenia, the incidence of postoperative sepsis was 28.2% (11/39) in 2003-2007 and 10.5% (6/57) in 2008-2011 ($P$ = 0.03; Table 4).

## DISCUSSION

To determine sarcopenia, we measured the major and minor axes of the psoas muscle; we did not use any area-measuring software. Using such software is sometimes a little complicated; in particular, the tracing of the psoas muscle area may not always be correct. In the current study, the data were normally distributed well, and so they were considered to be reliable. There is no apparent definition of sarcopenia based on the psoas muscle area.[5] In many reports, the definition of sarcopenia has been decided subjectively on the basis of data from examinees.[5,11] In the current study, on the basis of data from our previous study, sarcopenia was defined as less than the 5th percentile value of the psoas muscle area of healthy donors of each sex.[9] The data for the psoas muscle area of the donors, both males and females, were also normally distributed,[9] so it was reasonable to define a cutoff value for patients with sarcopenia. Although an area less than the 5th percentile of the psoas muscle area of healthy donors was defined as sarcopenia, 58.3% of male recipients and 35.6% of female recipients were diagnosed with sarcopenia. Not surprisingly, more recipients than healthy donors had central muscle loss.

In this study, preoperative sarcopenia was an independent predictor of mortality after LDLT. Associations with sarcopenia and a poor prognosis have been reported not only for transplant patients[5,12] but also for cancer patients.[11,13] Sarcopenia seems to reflect a surgeon's clinical impression of disease severity. Actually, in the current study, the Kaplan-Meier curve for patients with sarcopenia was significantly lower than the curve for patients without sarcopenia in the early period after LDLT, and approximately 40% of the deaths were due to postoperative sepsis or bleeding.

It has been reported that approximately 40% of patients with cirrhosis suffer from sarcopenia.[4] Although the mechanism of sarcopenia in patients with cirrhosis has not been clarified, one of the most important causes is thought to be malnutrition. A poor nutritional status has been suggested to increase the risk of posttransplant complications or mortality.[14,15] Malnutrition has been reported in 60% to 80% of patients

**TABLE 2. Univariate and Multivariate Analyses of the Impact of Sarcopenia and Other Clinical Characteristics on Overall Survival**

| Variable | All Patients | Univariate Analysis: *P* Value | Multivariate Analysis: Hazard Ratio | 95% Confidence Interval | *P* Value |
|---|---|---|---|---|---|
| Recipient age (years)* | 54.4 ± 9.6 | 0.81 | 1.00 | 0.96-1.04 | 0.99 |
| Donor age (years)* | 34.8 ± 10.4 | 0.16 | 1.02 | 0.99-1.05 | 0.21 |
| Recipient sex: male/female (n) | 103/101 | 0.41 | 1.09 | 0.54-2.19 | 0.81 |
| Recipient status: hospitalized/home (n) | 59/145 | 0.37 | 1.00 | 0.44-2.28 | 0.99 |
| Preoperative renal failure: yes/no (n) | 13/191 | 0.01 | 2.60 | 0.78-8.62 | 0.12 |
| BMI (kg/m$^2$)* | 23.6 ± 3.4 | 0.18 | 1.09 | 0.98-1.20 | 0.10 |
| Child-Pugh class: C/A + B (n) | 139/65 | 0.39 | 1.10 | 0.48-2.56 | 0.81 |
| MELD score: ≥20/<20 | 34/170 | 0.15 | 1.15 | 0.45-2.95 | 0.77 |
| GV/SLV ratio (%)* | 41.0 ± 8.1 | 0.80 | 0.99 | 0.95-1.03 | 0.63 |
| Sarcopenia: yes/no (n) | 96/108 | 0.02 | 2.06 | 1.01-4.20 | 0.047 |

*The data are presented as means and standard deviations.

**TABLE 3. Univariate and Multivariate Analyses of Risk Factors for Postoperative Sepsis**

| Variable | All Patients | Univariate Analysis: *P* Value | Multivariate Analysis: Hazard Ratio | 95% Confidence Interval | *P* Value |
|---|---|---|---|---|---|
| Recipient age (years)* | 54.4 ± 9.6 | <0.001 | 0.88 | 0.83-0.94 | <0.001 |
| Donor age (years)* | 34.8 ± 10.4 | 0.046 | 1.01 | 0.97-1.05 | 0.66 |
| Recipient sex: male/female (n) | 103/101 | 0.39 | 0.83 | 0.30-2.32 | 0.72 |
| Recipient status: hospitalized/home (n) | 59/145 | 0.03 | 2.20 | 0.70-6.91 | 0.18 |
| Preoperative renal failure: yes/no (n) | 13/191 | 0.01 | 2.45 | 0.49-12.2 | 0.28 |
| BMI (kg/m$^2$)* | 23.6 ± 3.4 | 0.66 | 1.19 | 1.03-1.38 | 0.02 |
| Child-Pugh class: C/A + B (n) | 139/65 | 0.82 | 0.43 | 0.12-1.61 | 0.21 |
| MELD score: ≥20/<20 | 34/170 | 0.04 | 1.71 | 0.49-5.95 | 0.40 |
| GV/SLV ratio (%)* | 41.0 ± 8.1 | 0.23 | 1.05 | 0.99-1.12 | 0.13 |
| Sarcopenia: yes/no (n) | 96/108 | 0.03 | 5.31 | 1.53-18.4 | 0.009 |

*The data are presented as means and standard deviations.

**TABLE 4. Incidence of Postoperative Sepsis**

| | Postoperative Sepsis [% (n/N)] | | |
|---|---|---|---|
| | 2003-2007 (n = 99) | 2008-2011 (n = 105) | *P* Value |
| All patients (n = 204) | 18.2 (18/99) | 6.7 (7/105) | 0.02 |
| Patients without sarcopenia (n = 108) | 11.7 (7/60) | 2.1 (1/48) | 0.07 |
| Patients with sarcopenia (n = 96) | 28.2 (11/39) | 10.5 (6/57) | 0.03 |

with cirrhosis. However, assessing the nutritional status of patients with liver dysfunction is difficult because of fluid collections caused by impaired protein synthesis in the liver.[16-18] The albumin and prealbumin levels do not necessarily reflect the nutritional status because hepatocellular protein synthesis is usually impaired in these patients. The assessment and interpretation of body weight are also difficult because of the presence of ascites, pleural effusion, and peripheral edema. Besides, sarcopenic, obese patients with respiratory and gastrointestinal tumors have recently been reported to have worse survival.[19] These facts may be the reasons that younger, high-BMI, and sarcopenic patients are at high risk for postoperative sepsis.

The incidence of postoperative sepsis was reduced even in patients with sarcopenia after the routine application of early enteral nutrition. However, the incidence was still high (10.5%). One of the reasons may be the lack of glutamine, especially in patients with sarcopenia. Glutamine is mainly synthesized in

skeletal muscle, and that is reduced in sarcopenic patients.[20] Additionally, we used an enteral nutrition formula that does not include glutamine, and it is thought that patients with sarcopenia suffer from glutamine depletion. Glutamine is an important nutrient in constructing the intestinal wall: a decrease in glutamine can weaken the intestinal wall, and postoperative sepsis due to bacterial translocation may occur.[21] Besides, it has recently been reported that portal glucose delivery stimulated not liver but instead muscle protein synthesis in an in vivo study.[22] Protein synthesis in patients with sarcopenia must be lower than that in patients without sarcopenia. Now, a prospective study using early enteral nutrition with or without glutamine is being planned and promoted.

As for the benefits of this study, the most important difference between DDLT and LDLT may be the timing of liver transplantation. It can be easier to control the timing of the operation with LDLT. If a patient with sarcopenia is diagnosed in a candidate for LDLT, liver transplantation can be deferred, and previous treatments for sarcopenia (ie, nutritional and physical therapy) can be applied. The diagnosis of sarcopenia before transplantation can be more useful in LDLT versus DDLT. Branched-chain amino acids (BCAAs) are a source of energy, modulate signal transduction as messengers in skeletal muscle, and prevent muscle atrophy.[16,23,24] On the other hand, previous studies have shown the impact of changes in BCAA levels on the immune system. In vitro studies have shown that the omission of a single BCAA from a medium of cultured lymphocytes completely abolishes protein synthesis and cellular proliferation.[25-27] Kakazu et al.[28,29] demonstrated that an increased concentration of BCAAs could restore the functions of dendritic cells harvested from patients with cirrhosis both in vitro and ex vivo. Preoperative BCAA supplementation may have effects not only in preventing central muscle loss but also in restoring immune function in patients with advanced liver cirrhosis.

In conclusion, sarcopenia is an independent predictor of mortality and a risk factor for sepsis after LDLT. The incidence of postoperative sepsis was reduced even in patients with sarcopenia after the routine application of early enteral nutrition. Sarcopenia may be an objective evaluation of malnutrition in transplant candidates, and the treatment of malnutrition may improve mortality rates after liver transplantation. Further studies with larger numbers are required.

## REFERENCES


1. Rosenberg IH. Summary comments. Am J Clin Nutr 1989;50:1231-1233.
2. Doherty TJ. Invited review: aging and sarcopenia. J Appl Physiol 2003;95:1717-1727.
3. Agarwal E, Miller M, Yaxley A, Isenring E. Malnutrition in the elderly: a narrative review. Maturitas 2013;76:296-302.
4. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:166-173.
5. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010;211:271-278.
6. Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant 2013;13:1549-1556.
7. Moore FA, Moore EE. The evolving rationale for early enteral nutrition based on paradigms of multiple organ failure: a personal journey. Nutr Clin Pract 2009;24:297-304.
8. Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Ninomiya M, Uchiyama H, et al. Bacterial sepsis after living donor liver transplantation: the impact of early enteral nutrition. J Am Coll Surg 2012;214:288-295.
9. Yoshizumi T, Shirabe K, Nakagawara H, Ikegami T, Harimoto N, Toshima T, et al. Skeletal muscle area correlates with body surface area in healthy adults. Hepatol Res; doi:10.1111/hepr.12119.
10. Shirabe K, Yoshimatsu M, Motomura T, Takeishi K, Toshima T, Muto J, et al. Beneficial effects of supplementation with branched-chain amino acids on postoperative bacteremia in living donor liver transplant recipients. Liver Transpl 2011;17:1073-1080.
11. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012;99:550-557.
12. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012;18:1209-1216.
13. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-6979.
14. Selberg O, Böttcher J, Tusch G, Pichlmayr R, Henkel E, Müller MJ. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997;25:652-657.
15. Pikul J, Sharpe MD, Lowndes R, Ghent CN. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation 1994;57:469-472.
16. Masuda T, Shirabe K, Yoshiya S, Matono R, Morita K, Hashimoto N, et al. Nutrition support and infections associated with hepatic resection and liver transplantation in patients with chronic liver disease. JPEN J Parenter Enteral Nutr 2013;37:318-326.
17. Stephenson GR, Moretti EW, El-Moalem H, Clavien PA, Tuttle-Newhall JE. Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001;72:666-670.
18. Merli M, Giusto M, Gentili F, Novelli G, Ferretti G, Riggio O, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010;30:208-214.
19. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 2012;31:583-601.
20. Biolo G, Zorat F, Antonione R, Ciocchi B. Muscle glutamine depletion in the intensive care unit. Int J Biochem Cell Biol 2005;37:2169-2179.
21. Karinch AM, Pan M, Lin CM, Strange R, Souba WW. Glutamine metabolism in sepsis and infection. J Nutr 2001;131(suppl):2535S-2538S.
22. Kraft G, Coate KC, Dardevet D, Farmer B, Donahue EP, Williams PE, et al. Portal glucose delivery stimulates

muscle but not liver protein metabolism. Am J Physiol Endocrinol Metab 2012;303:E1202-E1211.

23. Vente JP, Soeters PB, von Meyenfeldt MF, Rouflart MM, van der Linden CJ, Gouma DJ. Prospective randomized double-blind trial of branched chain amino acid enriched versus standard parenteral nutrition solutions in traumatized and septic patients. World J Surg 1991;15:128-132.
24. Bassit RA, Sawada LA, Bacurau RF, Navarro F, Martins E Jr, Santos RV, et al. Branched-chain amino acid supplementation and the immune response of long-distance athletes. Nutrition 2002;18:376-379.
25. Chuang JC, Yu CL, Wang SR. Modulation of human lymphocyte proliferation by amino acids. Clin Exp Immunol 1990;81:173-176.
26. Dauphinais C, Waithe WI. PHA stimulation of human lymphocytes during amino acid deprivation. Protein, RNA and DNA synthesis. J Cell Physiol 1977;91:357-367.
27. Waithe WI, Dauphinais C, Hathaway P, Hirschhorn K. Protein synthesis in stimulated lymphocytes. II. Amino acid requirements. Cell Immunol 1975;17:323-334.
28. Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M, Inoue J, et al. Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 2009;50:1936-1945.
29. Kakazu E, Kanno N, Ueno Y, Shimosegawa T. Extracellular branched-chain amino acids, especially valine, regulate maturation and function of monocyte-derived dendritic cells. J Immunol 2007;179:7137-7146.

ELSEVIER

# Two-step Selection Criteria for Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma

T. Yoshizumi, T. Ikegami, T. Toshima, N. Harimoto, H. Uchiyama, Y. Soejima, Y. Yamashita, K. Shirabe, and Y. Maehara

ABSTRACT

We have proposed risk factors for tumor recurrence, such as tumor nodule ≥5 cm and des-gamma-carboxy prothrombin ≥300 mAU/mL after living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). The aim of this study was to clarify the risk factors for HCC recurrence and mortality within our criteria. We enrolled 152 adult recipients who had undergone LDLT for end-stage liver disease with HCC who met our criteria. The recurrence-free survival rates after LDLT were calculated. Risk factors for tumor recurrence were identified. On univariate analysis, factors affecting recurrence-free survival were pretransplant treatment for HCC, neutrophil-to-lumphocyte ratio (NLR) >4, alpha-fetoprotein ≥400 ng/mL, ≥5 nodules, and bilobar tumor distribution. Multivariate analysis identified that NLR >4 and ≥5 nodules were independent risk factors for tumor recurrence after LDLT ($P = .003$ and $P = .002$, respectively). Two-step selection criteria enable selection of patients who have high-risk of tumor recurrence.

HEPATOCELLULAR CARCINOMA (HCC) is the fifth most common neoplasm worldwide and the third most common cause of cancer-related death. Its incidence is increasing because of the dissemination of hepatitis B and C virus infection.[1] Liver transplantation (OLT), which offers the theoretical advantage of removing both the tumor and the organ that are at risk of developing future malignancy, is an established therapy for HCC in patients with liver cirrhosis.[2] In Asian countries, religious, living donor OLT (LDLT) is a choice for treating such HCC patients after various treatments, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and/or hepatic resection.[3] We have reported the outcome of LDLT for otherwise unresectable and/or untreatable HCC patients and have proposed 2 risk factors for recurrence-free survival: tumor size >5 cm and des-gamma-carboxy prothrombin (DCP) levels >300 mAU/mL [Kyushu University (KU) criteria].[4,5] More LDLTs for HCC patients have been performed under the KU criteria, thus generating a larger cohort.

The neutrophil-to-lymphocyte ratio (NLR) has recently emerged as a useful prognostic factor for recurrence of several gastroenterologic malignancies. NLR ≥5 has been reported to be a marker of survival in colorectal cancer patients.[6] Recently, it has been demonstrated that a preoperative NLR ≥5 is an adverse predictor of recurrence-free survival for patients undergoing hepatic resection for HCC.[7] Furthermore, an elevated NLR significantly increases the risk of HCC recurrence after OLT.[8,9]

These data have encouraged us to investigate whether NLR could be a risk factor for HCC recurrence, to create new selection criteria for HCC patients undergoing LDLT. The aim of the present study was to clarify the risk factors for HCC recurrence and mortality after LDLT in patients who met the KU criteria and to create new selection criteria.

## PATIENTS AND METHODS

### Patients

One hundred fifty-eight adult recipients underwent LDLT for end-stage liver disease with HCC at KU Hospital between April 1999 and December 2011. Six recipients did not meet the KU criteria.

From the Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

This study was partly funded by a grant-in-aid (Grant 23591989) from the Ministry of Education, Science, and Culture in Japan.

Address reprint requests to Tomoharu Yoshizumi, MD, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. E-mail: yosizumi@surg2.med.kyushu-u.ac.jp

0041-1345/13/$–see front matter
http://dx.doi.org/10.1016/j.transproceed.2013.05.001

Therefore, 152 recipients were enrolled in the study. In 12 of 152 cases, LDLT was performed for indications other than HCC, and the 12 cases were included in this study as HCC was found on explant pathology. One hundred five recipients underwent pretransplant treatment for HCC, such as RFA, TACE, microwave coagulation therapy, and/or hepatic resection, depending on the recipient's liver function and tumor status. Graft types included left lobe with caudate lobe (LL+C) graft ($n = 95$), right lobe graft without the middle hepatic vein ($n = 52$), posterior segment graft ($n = 4$), and dual graft ($n = 1$). The etiology of liver cirrhosis was hepatitis C ($n = 109$), hepatitis B ($n = 27$), cryptogenic ($n = 6$), and alcohol abuse ($n = 5$), autoimmune hepatitis ($n = 3$), and primary biliary cirrhosis ($n = 2$). Our selection criteria to perform LDLT for HCC patients were as follows: (1) no modality except LDLT available to cure the patients with HCC; (2) no extrahepatic metastasis; and (3) no major vascular infiltration.[4,5] There were no restrictions on tumor size, number of nodules, or pretransplant treatment. Since we proposed the KU criteria, we have not performed LDLT for HCC patients who have both tumor size >5 cm and DCP level >300 mAU/mL.

Pretransplant imaging was used to estimate number of nodules, up-to-seven criteria, and Milan criteria. Alpha-fetoprotein (AFP) and NLR were measured just prior to LDLT.

## Donor and Graft Selection

Donors were selected from candidates who hoped to be living donors.[10] Donors were required to be within the third degree of consanguinity with recipients or spouses and to be between 20 and 65 years of age. Eligible donors proceeded to the imaging studies, including chest and abdominal X-rays and 3-mm-slice computed tomography (CT) scans for graft volumetric analysis. Three-dimensional CT was introduced for volumetric analysis and delineation of vascular anatomy. The standard liver weight (SLW) of recipients was calculated according to the formula of Urata.[10] Graft weight (GW) was predicted by CT volumetric analysis. Our decision about graft type for recipients was based on the preoperatively predicted GW-to-SLW ratio. LL+C graft was used when the preoperatively predicted GW-to-SLW ratio was >35%. When GW-to-SLW ratio with LL+C graft was <35% and remnant donor liver volume after right lobectomy was >35%, right lobe graft was used. Posterior segment graft was considered when the donor's vascular anatomy was suitable to take a posterior segment.

## Postoperative Management

Immunosuppression was initiated using a protocol based on either tacrolimus (Prograf; Astellas Pharma Inc, Tokyo, Japan) or cyclosporine (Neoral; Novartis Pharma K.K., Tokyo, Japan) with steroid and/or mycophenolate mofetil (MMF; Chugai Pharmaceutical Co Ltd, Tokyo, Japan). A target trough level of tacrolimus was set at 10 ng/mL for 3 months after LDLT, followed by 5 to 10 ng/mL thereafter. A target trough level of cyclosporine was set at 250 ng/mL for 3 months after LDLT, followed by 150 to 200 ng/mL thereafter. Methylprednisolone was initiated on the day of LDLT, then tapered and converted to prednisolone 7 days after LDLT. Prednisolone treatment was tapered and discontinued 6 months after LDLT. MMF was used in 134 recipients and was started at 1 g/d on the day after LDLT, then tapered and discontinued until 6 months after LDLT. A trough level was not measured for MMF.

All patients were followed monthly, and the median follow-up period was 1660 days, with 791 days and 2617 days as the 25th and 75th percentiles, respectively.

**Table 1. Risk Factors for Tumor Recurrence: Univariate Analysis**

| Variables | *n* | Recurrence-free survival (%) 1 y | 3 y | 5 y | *P* value |
|---|---|---|---|---|---|
| Recipient variables | | | | | |
| Gender | | | | | |
| Male | 85 | 91.2 | 89.8 | 87.5 | .75 |
| Female | 67 | 98.4 | 88.3 | 88.3 | |
| Age (y) | | | | | |
| >60 | 63 | 91.5 | 89.2 | 89.2 | .88 |
| ≤60 | 89 | 96.4 | 89.9 | 87.7 | |
| Etiology | | | | | |
| HCV | 110 | 94.3 | 89.9 | 88.0 | .90 |
| Others | 42 | 94.4 | 88.1 | 88.1 | |
| Pretransplant MELD | | | | | |
| <15 | 119 | 94.6 | 88.5 | 86.9 | .44 |
| ≥15 | 33 | 93.6 | 93.6 | 93.6 | |
| Diabetes mellitus | | | | | |
| Yes | 37 | 91.1 | 86.7 | 81.3 | .43 |
| No | 115 | 95.4 | 90.2 | 90.2 | |
| NLR | | | | | |
| >4 | 22 | 84.7 | 72.8 | 54.6 | .0012 |
| ≤4 | 130 | 95.9 | 92.0 | 92.0 | |
| Splenectomy | | | | | |
| Yes | 94 | 93.1 | 88.5 | 88.5 | .94 |
| No | 58 | 96.4 | 90.7 | 88.5 | |
| Calcineurin inhibitor | | | | | |
| TAC | 71 | 95.5 | 90.4 | 90.4 | .82 |
| CyA | 78 | 93.3 | 88.6 | 86.5 | |
| Donor variables | | | | | |
| Gender[a] | | | | | |
| Male | 109 | 96.0 | 91.3 | 89.5 | .13 |
| Female | 42 | 90.2 | 84.5 | 84.5 | |
| Donor age (y)[a] | | | | | |
| >40 | 37 | 100 | 96.4 | 96.4 | .10 |
| ≤40 | 114 | 92.6 | 87.2 | 85.6 | |
| GW–SLW ratio | | | | | |
| <35 | 32 | 89.6 | 81.6 | 81.6 | .19 |
| ≥35 | 120 | 95.6 | 91.4 | 89.8 | |
| Tumor variables | | | | | |
| Pretransplant treatment for HCC | | | | | |
| Yes | 105 | 91.7 | 84.4 | 82.6 | .01 |
| No | 47 | 100 | 100 | 100 | |
| AFP (ng/mL) | | | | | |
| ≥400 | 25 | 82.9 | 71.9 | 62.9 | <.0001 |
| <400 | 127 | 96.6 | 92.8 | 92.8 | |
| Bilobar tumor distribution | | | | | |
| Yes | 69 | 89.0 | 81.8 | 79.4 | .003 |
| No | 83 | 98.7 | 95.8 | 95.8 | |
| Number of nodules | | | | | |
| ≥5 | 38 | 77.5 | 63.4 | 63.4 | <.0001 |
| <5 | 114 | 100 | 97.8 | 96.0 | |

MELD, Model for End-stage Liver Disease; NLR, neutrophil-to-lymphocyte ratio; TAC, tacrotimus; CyA, cyclosporine; GW, graft weight; SLW, standard liver weight; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; LDLT, living donor liver transplantation; HCV, hepatitis C virus.
[a]A case that used dual graft was excluded.

## Post-LDLT Tumor Recurrence and Risk Factors

All patients had abdominal CT scan every 3 months and had chest CT scan and bone scintigraphy every 6 months for 5 years after

**Table 2. Risk Factors for Tumor Recurrence: Multivariate Analysis**

| Variables | Odds ratio | 95% CI | *P* value |
|---|---|---|---|
| Number of nodules ≥5 | 10.3 | 2.04–77.7 | .002 |
| NLR >4 | 7.73 | 2.04–26.4 | .003 |
| Pretransplant treatment for HCC[a] | 4.81 | 0.63–∞ | .14 |
| AFP ≥400 ng/mL | 2.13 | 0.46–8.56 | .39 |
| Bilobar distribution | 0.92 | 0.12–8.87 | >.999 |

NLR, neutrophil-to-lymphocyte ratio; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; HCC, hepatocellular carcinoma.
[a]Median unbiased estimates.

LDLT. Tumor recurrence was defined when any imaging studies, such as chest or abdominal CT scan or bone scintigraphy, revealed recurrence of HCC. Recurrence-free survival was defined as the time between LDLT and tumor recurrence. Univariate and multivariate analyses were performed to identify the factors associated with the recurrence-free survival after the LDLT.

### Statistical Analysis

Recurrence-free survival rates were calculated by the Kaplan–Meier product-limited method. Cox regression analysis was applied to the multivariate analyses. Variables that were used for the analysis included recipient age, donor age, Model for End-stage Liver Disease score, presence of hepatitis C virus, presence of diabetes mellitus, recipient sex, donor sex, GW-to-SLW ratio, pretransplant treatment for HCC, number of nodules obtained by imaging study, pretransplant NLR, pretransplant AFP, tumor distribution, splenectomy, and a type of calcineurin inhibitor. All statistical analyses were performed using JMP 9.0 software (SAS, Inc, Cary, NC, USA). A *P* value of <.05 was considered significant.

## RESULTS

Fifty-seven of 152 recipients (38%) did not meet the Milan criteria. The 1-, 3-, and 5-year recurrence-free survival rates in the recipients were 94.4%, 89.4%, and 88.1%, respectively. Sixteen of the 152 recipients had HCC recurrence after LDLT. Fifteen of those recurrent recipients did not meet the Milan criteria but were within KU criteria. Univariate analysis revealed that pretransplant treatment for HCC, NLR >4, AFP ≥400 ng/mL, ≥5 nodules, and bilobar tumor distribution were risk factors for HCC recurrence after LDLT ($P = .01$, $P = .001$, $P < .0001$, $P < .0001$, and $P = .003$, respectively; Table 1). Multivariate analysis revealed that NLR >4 and ≥5 nodules were independent risk factors for tumor recurrence after LDLT ($P = .003$ and $P = .002$, respectively; Table 2). The enrolled 152 recipients were divided into 3 groups according to score for risk factors for HCC recurrence. The recipients in group 1 had no risk factor ($n = 97$). The recipients in group 2 had a sum of risk factors equal to 1 ($n = 50$). The recipients in group 3 had a sum of risk factors equal to 2 ($n = 5$). The 1-, 3-, and 5-year recurrence-free survival rates of recipients in group 1 were all 100%. The 1-, 3-, and 5-year recurrence-free survival rates in group 2 were 89.1%, 74.0%, and 69.4%, respectively. The 1-year recurrence-free survival rate in group 3 was 30.0%. The 3- and 5-year recurrence-free survival rates were not available. Duration of LDLT and recurrence was 74 days, 89 days, and 219 days, respectively. Twelve recipients in group 2 had HCC recurrences after LDLT. The mean duration of LDLT and recurrence was 571 days. The recurrence-free survival rates of recipients in group 3 were significantly worse than those of recipients in group 1 and group 2 ($P < .0001$; Fig 1).




**Fig 1.** Recurrence-free recipient survival after living donor liver transplantation for hepatocellular corcinoma (HCC). The 152 recipients were divided into 3 groups according to score for risk factors for HCC recurrence. The 1-, 3-, and 5-year recurrence-free survival rates of recipients in group 1 ($n = 97$) were all 100%. The 1-, 3-, and 5-year recurrence-free survival rates in group 2 ($n = 50$) were 89.1%, 74.0%, and 69.4%, respectively. The 1-year recurrence-free survival rate in group 3 ($n = 5$) was 30.0%. The recurrence-free survival rates of recipients in group 3 were significantly worse than those of recipients in groups 1 and 2 ($P < .0001$).

## DISCUSSION

It is crucial to exclude HCC patients with high risks of tumor recurrence. We should focus on how we can predict the




**Fig 2.** Two-step selection criteria to prevent hepatocellular corcinoma (HCC) recurrence after living donor liver transplantation (LDLT). When HCC patients have a maximum tumor size ≥5 cm and des-gamma carboxy prothrombin ≥300 mAU/mL (beyond the Kyushu University [KU] criteria), they are contraindicated for LDLT. Even when HCC patients meet the KU criteria, those with ≥5 nodules and neutrophil-to-lymphocyte ratio >4 are contraindicated for LDLT. The other HCC patients are good candidates for LDLT.

high-risk patients before LDLT. Therefore, for univariate and multivariate analysis, we chose variables that were obtained before transplantation. We observed that NLR >4 and ≥5 nodules were independent risk factors of HCC recurrence after LDLT for patients with HCC who met the KU criteria. The recipients were well stratified according to the number of risk factor.

By using receiver operating characteristics (ROC) analysis for tumor recurrence after LDLT, the area under the ROC curve of NLR was 0.695. A cutoff value of NLR was set as 4 using the analysis (data not shown). There are several possible mechanisms to explain the predictive role of preoperative elevated NLR.[11] Infiltration of proinflammatory macrophages, cytokines, and chemokines in the tumor microenvironment can boost tumor growth, invasion, and metastases.[12,13] Furthermore, high expressions of granulocyte colony-stimulating factor in tumor tissue and macrophage colony-stimulating factor in peritumoral tissue are associated with the elevated circulating neutrophils and poor prognosis.[14] However, reduced lymphocyte infiltration is a predictor of HCC recurrence after OLT.[15] The interpretation of NLR in patients with end-stage liver disease, often complicated with hypersplenism and pancytopenia, requires to need caution. Therefore, there may be limitation for the evaluation in such patients. Mean white blood cell (WBC) count of the patients was 3466/mm$^3$ in the present study (range 1060–8700). It was interesting that WBC count of patients with NLR >4 were higher than that of patients with NLR ≤4 ($P = .003$).

We will continue to use the KU criteria as the first exclusion criteria for LDLT. According to our results, we can use 2-step selection criteria for HCC patients as shown in Fig 2. In the first step, which is actually the same as the KU criteria that we used, patients are selected by tumor size and level of DCP. For patients who meet the KU criteria, patients are selected by NLR level and number of nodules.

In conclusion, our 2-step selection criteria enable selection of patients who have high risk of tumor recurrence. LDLT should not be performed in patients with HCC with NLR >4 and ≥5 nodules to achieve better outcome.

## REFERENCES

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet*. 2003;362:1907–1917.

2. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol*. 2011;12:654–662.

3. Yoshizumi T, Shirabe K, Soejima Y, Taketomi A, Ikegami T, Uchiyama H, et al. Living donor liver transplantation in patients who have received pretransplant treatment for hepatocellular carcinoma. *Transplantation*. 2011;91:e61–e62.

4. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. *Transplantation*. 2007;83:893–899.

5. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. *Transplantation*. 2009;87:531–537.

6. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. *J Surg Oncol*. 2005;91:181–184.

7. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. *World J Surg*. 2008;32:1757–1762.

8. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. *Ann Surg*. 2009;250:141–151.

9. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. *PLoS One*. 2011;6:e25295.

10. Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, et al. The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. *Transpl Int*. 2008;21:833–842.

11. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. *Transplantation*. 2011;91:1279–1285.

12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454:436–444.

13. Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. *Surg Today*. 2012;42:1–7.

14. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *J Clin Oncol*. 2008;26:2707–2716.

15. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. *J Hepatol*. 2006;45:246–253.

TRANSPLANTATION

# 3D printing of the liver in living donor liver transplantation

*Toru Ikegami and Yoshihiko Maehara*

**Advances in 3D printing techniques are gathering pace. With regard to living donor liver transplantation (LDLT), 3D printing could enable accurate assessment of liver volume and accurate visualization of liver anatomy, and could be particularly helpful for paediatric LDLT.**

Ikegami, T. & Maehara, Y. *Nat. Rev. Gastroenterol. Hepatol.* 10, 697–698 (2013); published online 15 October 2013; doi:10.1038/nrgastro.2013.195

Within the past few years, advances in 3D printing techniques have led to its introduction in medical fields. Zein *et al.*[1] have now used 3D printing in the setting of living donor liver transplantation (LDLT), by creating semi-transparent hepatic prototypes containing visible hepatic vessels and bile ducts, and a near-identical volume to the donor's liver.

Advances in multidetector CT and data processing techniques mean that virtual 3D imaging, virtual hepatectomy and virtual volumetry are now routinely performed during liver surgery.[2–4] However, because 3D images are visualized on a flat computer screen, surgeons are unable to manipulate the visualized liver with their hands. The development of 3D printing can overcome this limitation by enabling us to print and manipulate prototypic objects. Moreover, by carefully selecting the casting materials and dyes, it is possible to use different colours, transparencies, textures and consistencies to generate a prototype that mimics the real-life object.

For LDLT, it is essential to accurately predict the volume of a procured liver graft and to plan the resection route. If pre-transplant volumetry overestimates the volume of a procured liver, the recipient might develop small-for-size graft syndrome, which might result in graft loss—although graft quality is ultimately determined by multiple factors such as donor age, graft steatosis, disease severity and portal venous pressure.[5–7] Furthermore, if the resection route deviates from the planned route, it might lead to the procurement of a smaller-than-expected graft or increase the risk of donor complications caused by surgical injury to the donor's remnant liver. However, the liver is not transparent and the internal structures, especially the blood vessels and biliary tracts, are not visible. A 3D model that can be manipulated and that enables surgeons to visualize the internal structures could, therefore, overcome these issues.

> "A 3D-printed model of the liver could help to reduce the risk of large-for-size syndrome..."

The clinical application of 3D printing, as reported by Zein *et al.*,[1] has two main advantages, namely accurate assessment of the liver volume and accurate visualization of liver anatomy with easily visible structures. In terms of the accuracy of assessing the explanted liver volume, Zein *et al.*[1] reported that the 95% confidence interval was 28.8 ml (2.8% of the mean native liver volume), which suggests that the method is very accurate, especially compared with earlier reports of 3D virtual volumetry, for which the accuracy ranged from 5–25%.[2–4] The discrepancy between the pre-transplant expected liver volume and the actual volume or weight, even with accurate imaging and reconstruction, has been widely discussed. Factors that contribute to this discrepancy include conversion of intraoperative graft weight/volume at a rate of 1.0 g/ml, drainage of intrahepatic blood after procurement, dehydration of the perfused liver by hypertonic preservation solution, unevenness or deviation of the resection plane, and the loss of perfusion pressure after explanting the procured liver.[2–4] Clearly, accurately determining liver volume is difficult, even with volumetry. Zein *et al.*[1] determined actual graft volume, not weight, after procurement but before perfusion using a liquid displacement technique to minimize bias, enabling them to accurately measure the length, width, height and volume of the graft.

Although 3D printing techniques are suitable for adult-to-adult LDLT, they might be particularly useful in the setting of paediatric LDLT. In young children and small babies, one of the major obstacles to successful LDLT is large-for-size syndrome, in which the transplanted graft cannot be placed in a small abdominal cavity.[8] Large-for-size syndrome is associated with an increased risk of vascular complications including portal vein thrombosis, hepatic artery thrombosis and hepatic venous stenosis. Tissue oxygenation might also be impaired because of inappropriate compression.[8] To minimize these complications, surgical techniques have been developed to procure small grafts, including reduced lateral segment, mono-segment or reduced mono-segment grafts.[9] A graft-to-recipient weight ratio >4.0 is associated with increased risk of large-for-size syndrome, although a sculptured graft can be placed in the upper right abdominal cavity of a baby providing the vasculature is properly aligned.[8,9] A 3D-printed model of the liver could help to reduce the risk of large-for-size syndrome, especially if using reduced grafts to minimize tissue loss from the potential donor, and if the abdominal cavity of the recipient is also printed to test whether the planned graft fits the cavity.

> "Another benefit of 3D printing is the ability to create a structure with visible interior structures"

**"...we believe that 3D printing is eminently suitable for LDLT"**

Another benefit of 3D printing is the ability to create a structure with visible interior structures. As Zein *et al.*[1] showed in their figures, the portal and hepatic veins are visible from the cut surface of the prototype liver grafts. During hepatic resection, the surgeon exposes structures by dissecting opaque brown-coloured hepatic parenchyma and divides them when necessary. A deviation from the planned resection line of 1 cm might result in migration into a different segment, especially around the hepatic hilum. Thus, recognizing the structures along the resection line as well as the interior structures likely to be encountered during resection should fill the surgeon with confidence to perform a safe and secure hepatectomy. Indeed, 3D printing might be most useful when planning curvilinear hepatic resection, including subsegmentectomy of segments 7 or 8, because the right subphrenic dome portion of the liver is very deep and resection requires full mobilization of the right liver with the surgeon's right hand.[10] Such procedures are very difficult to visualize, even with 3D virtual simulation, unlike the flat cutting plane in hepatic lobectomy during donor surgery.

Some limitations of 3D printing in liver surgery include its high cost, the time needed (often >1 day) to generate the 3D prototypes, and the limited qualities and properties of the printing techniques and materials, which limit the transparency, flexibility and durability of the prototypes. Because of its high cost, 3D printing might not be justified for routine use in liver surgery. The long time to generate the 3D prototypes also limits the use of 3D printing to elective cases, preventing its use in acute cases. Nevertheless, w, and that further developments in 3D printing technologies, together with increasing availability, will lead to its wider application, enabling improvements in patient care, enhanced surgical education and the opening of new research fields.

*Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan (T. Ikegami, Y. Maehara).*
*Correspondence to: Y. Maehara*
*maehara@surg2.med.kyushu-u.ac.jp*

**Competing interests**
The authors declare no competing interests.

1. Zein, N. N. *et al.* 3-dimentional (3D) print of liver for preoperative planning in live donor liver transplantation. *Liver Transpl.* http://dx.doi.org/10.1002/lt.23729.
2. Yoneyama, T. *et al.* Coefficient factor for graft weight estimation from preoperative computed tomography volumetry in living donor liver transplantation. *Liver Transpl.* **17**, 369–372 (2011).
3. Kim, K. W. *et al.* Right lobe estimated blood-free weight for living donor liver transplantation: accuracy of automated blood-free CT volumetry—preliminary results. *Radiology* **256**, 433–440 (2010).
4. Frericks, B. B., Kiene, T., Stamm, G., Shin, H. & Galanski, M. CT-based liver volumetry in a porcine model: impact on clinical volumetry prior to living donated liver transplantation [German]. *Rofo* **176**, 252–257 (2004).
5. Soejima, Y. *et al.* Left lobe living donor liver transplantation in adults. *Am. J. Transplant.* **12**, 1877–1885 (2012).
6. Kiuchi, T., Onishi, Y. & Nakamura, T. Small-for-size graft: not defined solely by being small for size. *Liver Transpl.* **16**, 815–817 (2010).
7. Ikegami, T. *et al.* Primary graft dysfunction after living donor liver transplantation is characterized by delayed functional hyperbilirubinemia. *Am. J. Transplant.* **12**, 1886–1897 (2012).
8. Shehata, M. R. *et al.* Pediatric liver transplantation using reduced and hyper-reduced left lateral segment grafts: a 10-year single-center experience. *Am. J. Transplant.* **12**, 3406–3413 (2012).
9. Kasahara, M. *et al.* Living donor liver transplantation with hyperreduced left lateral segments. *J. Pediatr. Surg.* **43**, 1575–1578 (2008).
10. Kishi, Y. *et al.* Resection of segment VIII for hepatocellular carcinoma. *Br. J. Surg.* **99**, 1105–1112 (2012).

RECTAL CANCER

# Is 'watch and wait' a safe option for rectal cancer?

*Bruce D. Minsky*

**The standard treatment for stage III rectal cancer is chemoradiation followed by radical surgery. Recent trials have recommended a 'watch and wait' approach for patients who achieve a complete clinical response. A new study reports that 51% of patients who achieved a sustained complete clinical response did not require radical surgery.**

Minsky, B. D. *Nat. Rev. Gastroenterol. Hepatol.* **10**, 698–700 (2013); published online 22 October 2013; doi:10.1038/nrgastro.2013.201

The conventional adjuvant treatment for stage III rectal cancer is preoperative radiation with concurrent chemotherapy (chemoradiation) followed by radical surgery 4–8 weeks later. Radical surgery is not performed in some clinical settings. Historically, these settings have included early stage tumours, medically inoperable disease and patient refusal. In the past decade, not immediately treating patients with radical surgery has been used in patients who respond well to preoperative chemoradiation, which could enable some patients to avoid surgery altogether. A recent report by Habr-Gama *et al.*[1] is the fifth prospective trial examining this 'watch and wait' approach.

Although patients with rectal cancer can be cured without surgery, the results are often suboptimal. For example, Brierley and colleagues treated patients who refused surgery or had unresectable or medically inoperable disease with pelvic radiation alone and achieved a 5-year survival of 27%.[2] By contrast, preoperative chemoradiation followed by radical surgery results in 75% 5-year survival.[3]

Four prospective series have reported on chemoradiation followed by observation, in addition to the current study by Habr-Gama and co-workers (Table 1). An early series published in 2004 by Habr-Gama included 265 patients.[4] Overall, 27% achieved a complete clinical response (cCR) after chemoradiation and were selected for observation with close follow-up. Patients with stage cT1–3 disease were included and those who developed a local recurrence in the first year of follow-up were excluded from the analysis. Over a mean follow-up of 57 months, 3% of the patients had a luminal recurrence, 4% developed distant metastasis and 100% survival at 5 years was reported. In a subsequent update published in 2006, the local

**"Selecting patients for a nonoperative approach on the basis of tumour response is reasonable"**

# Prognostic Factors Affecting Survival at Recurrence of Hepatocellular Carcinoma After Living-Donor Liver Transplantation: With Special Reference to Neutrophil/Lymphocyte Ratio

*Norifumi Harimoto, Ken Shirabe, Hidekazu Nakagawara, Takeo Toshima, Yo-ichi Yamashita, Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Tetsuo Ikeda, and Yoshihiko Maehara*

**Background.** In living-donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC), it is important to predict not only who may be susceptible to recurrence but also who may survive longer. The neutrophil/lymphocyte ratio (NLR) is useful to properly assess the patient without decreasing the long-term survival after LDLT. In this study, we investigated the relationship between NLR and prognosis of patients with recurrent HCC after LDLT.
**Methods.** In total, 167 LDLTs for HCC were enrolled in this study. Clinicopathologic factors for HCC recurrence after LDLT were investigated and prognostic factors were examined with respect to survival.
**Results.** The following factors were found to be significant in patients with HCC recurrence compared with the controls: α-fetoprotein ≧300 ng/mL, des-γ-carboxyprothrombin ≧300 mAU/mL, NLR ≧4, tumor number >3, tumor size ≧5 cm, duration of last treatment of HCC to LDLT <3 months, Milan criteria exceeded, histologic tumor number ≧10, histologic tumor size >5 cm, poor differentiation, presence of histologic vascular invasion, adjuvant chemotherapy, and interferon therapy against patients with hepatitis C virus. Male sex, interferon therapy against patients with hepatitis C virus, α-fetoprotein ≧300 ng/mL at recurrence, NLR ≧4 at recurrence, and nonsurgical resection for recurrent HCC were significantly related to poor prognosis. The 3-year survival rate after recurrence was 0% in patients with NLR ≧4 and 43.6% in patients with NLR <4. NLR was reelevated after LDLT in patients who later died; however, NLR gradually decreased in surviving patients.
**Conclusion.** NLR at recurrence is a prognostic factor affecting survival after recurrence in LDLT for HCC.

**Keywords:** Hepatocellular carcinoma, Living-donor liver transplantation, Recurrence, Neutrophil/lymphocyte ratio, Biomarker.

(*Transplantation* 2013;96: 1008–1012)

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world (*1, 2*). Because of advances in the diagnosis and management of HCC, significant improvements in the overall survival rate for HCC after hepatectomy have been achieved. However, even when curative resection is performed, the high postoperative recurrence rate remains an issue. Liver transplantation (LT) is currently the treatment of choice for early unresectable HCC owing to poor liver function and with candidate selection according to the Milan criteria (one nodule of 5 cm or two to three nodules all of 3 cm) (*3, 4*). Some LT centers have expanded the criteria, such as the up-to-seven criteria (*5*), because of the concern that the Milan criteria are too stringent. In Japan, some biomarkers, such as α-fetoprotein (AFP), des-γ-carboxyprothrombin (DCP), or neutrophil/lymphocyte ratio (NLR), in addition to the tumor size and the number of tumors, have been reported to be useful to properly assess the candidate without decreasing the long-term survival after living-donor LT (LDLT) (*6–8*).

A high NLR has been reported to be a predictor of poor survival after hepatic resection, radiofrequency ablation, transarterial chemoembolization, and LT for HCC. We recently showed that NLR was an important prognostic factor in patients with HCC after hepatic resection (*9*) and patients who underwent LDLT (*10*).

The authors declare no funding or conflicts of interest.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Address correspondence to: Norifumi Harimoto, M.D., Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
E-mail: nharimotoh1@fukuoka.email.ne.jp
N.H. participated in the research design, data analysis, and writing of the article. K.S., T.I., and Y.M. contributed to the discussion and reviewed the article. H.N., T.T., and Y.Y. participated in the data collection. T.I., T.Y., and Y.S. participated in the research design.
Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.transplantjournal.com).
Received 28 May 2013. Revision requested 13 June 2013.
Accepted 15 July 2013.

ISSN: 0041-1337/13/9611-1008
DOI: 10.1097/TP.0b013e3182a53f2b